Research and application of herbal medicine in the treatment of chronic kidney disease since the 21st century: A visualized bibliometric analysis

Xu, Yunling; Chen, Jia; Wang, He; Lu, Ying

doi:10.3389/fphar.2022.971113

Cited by 4 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bibliometric analysis is an effective and feasible method for understanding research trends and focal areas within a given field, ultimately aiding researchers and clinicians in shaping future investigations and clinical treatments. [35,36] This bibliometric analysis investigated the relationship between the gut microbiota and CKD.…”

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of the Relationship between Gut Microbiota and Chronic Kidney Disease from 2001–2022

Tao,

Huo,

Chen

2024

Integr Med Nephrol Androl

View full text Add to dashboard Cite

Background: The gut microbiota is closely associated with chronic kidney disease (CKD) development and prognosis. However, a comprehensive understanding of publication trends and research focuses within this domain remains limited. This study aimed to elucidate the relationship between the gut microbiota and CKD through a bibliometric analysis. Methods: Literature published between 2001 and 2022 on gut microbiota and CKD was obtained from the Web of Science Core Collection database. Bibliometric analysis tools such as VOSviewer and CiteSpace were used to analyze research trends in this area. Results: We extracted 758 articles for further analysis. China ranked first with 240 published documents, followed by the USA with 211. However, the USA ranked first regarding citation frequency with 11,380 citations, while China ranked second. The University of California Irvine and Kidney International emerged as the leading institution and journal, respectively, with the former leading in document production and citations. Although Kidney International featured fewer documents than other journals, it exhibited the highest citation count. The keywords representing the research interests mainly included: (1) gut microbiota influences the development of CKD, (2) application of probiotics in the treatment of CKD, and (3) potential mechanism of gut microbiota in CKD. Conclusion: Our analysis indicates significant advancements in understanding the association between gut microbiota and CKD. It also provides a comprehensive overview of publication trends, research hotspots, and frontiers, which may provide guidelines for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of the Relationship between Gut Microbiota and Chronic Kidney Disease from 2001–2022

Tao,

Huo,

Chen

2024

Integr Med Nephrol Androl

View full text Add to dashboard Cite

show abstract

“…In traditional medicine in the East and West, herbal prescriptions that are composed of several medicinal plants have been used to alleviate fibrotic diseases of the major organs, including the liver, kidneys, and lungs [11][12][13]. Interestingly, plant extracts with these effects contain several polyphenolic compounds in common, and studies on the pharmacological effects of these compounds are attracting attention [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential and Mechanisms of Rosmarinic Acid and the Extracts of Lamiaceae Plants for the Treatment of Fibrosis of Various Organs

Boo

2024

Antioxidants

View full text Add to dashboard Cite

Fibrosis, which causes structural hardening and functional degeneration in various organs, is characterized by the excessive production and accumulation of connective tissue containing collagen, alpha-smooth muscle actin (α-SMA), etc. In traditional medicine, extracts of medicinal plants or herbal prescriptions have been used to treat various fibrotic diseases. The purpose of this narrative review is to discuss the antifibrotic effects of rosmarinic acid (RA) and plant extracts that contain RA, as observed in various experimental models. RA, as well as the extracts of Glechoma hederacea, Melissa officinalis, Elsholtzia ciliata, Lycopus lucidus, Ocimum basilicum, Prunella vulgaris, Salvia rosmarinus (Rosmarinus officinalis), Salvia miltiorrhiza, and Perilla frutescens, have been shown to attenuate fibrosis of the liver, kidneys, heart, lungs, and abdomen in experimental animal models. Their antifibrotic effects were associated with the attenuation of oxidative stress, inflammation, cell activation, epithelial–mesenchymal transition, and fibrogenic gene expression. RA treatment activated peroxisomal proliferator-activated receptor gamma (PPARγ), 5′ AMP-activated protein kinase (AMPK), and nuclear factor erythroid 2-related factor 2 (NRF2) while suppressing the transforming growth factor beta (TGF-β) and Wnt signaling pathways. Interestingly, most plants that are reported to contain RA and exhibit antifibrotic activity belong to the family Lamiaceae. This suggests that RA is an active ingredient for the antifibrotic effect of Lamiaceae plants and that these plants are a useful source of RA. In conclusion, accumulating scientific evidence supports the effectiveness of RA and Lamiaceae plant extracts in alleviating fibrosis and maintaining the structural architecture and normal functions of various organs under pathological conditions.

show abstract

“…7 In recent years, herbal therapies have been recognized as a dietary supplement for the treatment of various diseases, including cancer, diabetes, and CKD. [8][9][10][11] In clinical investigations, it has been demonstrated that numerous of herbal remedies have renoprotective effects and improve the outcomes of diseases by activating antioxidant defense mechanisms and reducing proinflammatory signaling pathways. [12][13] For instance, previous study found that curcumin therapy for three months reduced the levels of inflammation-related markers in CKD patients receiving hemodialysis.…”

Section: Introductionmentioning

confidence: 99%

Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study

Wongmanit,

Tungsukruthai,

Phetkate

et al. 2024

Pharmacogn J.

View full text Add to dashboard Cite

Background: Chronic kidney disease is a major public health issue, and due to resource constraints, many can't access dialysis. C. citratus, lemongrass is globally prevalent and known to increase urine output without toxicity. Objective: To examine the safety of C. citratus in patients with CKD stage 3. Materials and Methods: The major compound of C. citratus was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or C. citratus groups. The control group received a placebo, whereas the C. citratus group received 900 mg of C. citratus daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na + , K + , Cl -, and HCO3, and other biochemical parameters. Results: HPLC showed C. citratus contains of phenolic compounds. Clinically, C. citratus group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K + and Cl level. The level of blood Na + was significant increase at day30 (p < 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p < 0.05) and a significant increase of Cland SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na + , K + , HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. Conclusion: Dietary supplementation with C. citratus may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.

show abstract

Research and application of herbal medicine in the treatment of chronic kidney disease since the 21st century: A visualized bibliometric analysis

Cited by 4 publications

References 40 publications

Bibliometric Analysis of the Relationship between Gut Microbiota and Chronic Kidney Disease from 2001–2022

Bibliometric Analysis of the Relationship between Gut Microbiota and Chronic Kidney Disease from 2001–2022

Therapeutic Potential and Mechanisms of Rosmarinic Acid and the Extracts of Lamiaceae Plants for the Treatment of Fibrosis of Various Organs

Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study

Contact Info

Product

Resources

About